Figure 1. Chemical Structure Of Valrubicin (Valstar 1)
Valstar Solution, Concentrate
Product Images NDC 67979-001
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Valstar (NDC 67979-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Endo Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2. Comparison Of Mean Auc0-6 Hours In Valstar Clinical Studies (n=number Of Patients) (Valstar 2)
Total serum anthracyclines for a clinical study was measured in nmoles/L-hr. Results of a comparison of the mean AUC values of 0-8 hours in the VALSTAR clinical studies are presented in a graph with increasing values up to 20,000. Dosages of two-week typical TUR, extensive perforated IV infusion, and TUR bladder for a patient subset of a clinical study are also listed. No additional information is available from the given text.*
Vial Label (Valstar 3)
This is a warning for a solution that should not be administered without diluting it first. The enclosed package insert should be consulted for proper handling. The solution should be stored in a refrigerator between 2°- 8° C (36°- 46° F), and it is sterile, without preservatives. It is distributed by a company in Malvern, PA and manufactured by a company in Latina Scalo, Italy. It is not for use by injection or intravenous means.*
Carton Image (Valstar 4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
